All Comments by
- Jean-François Foncin on San Diego: What—3 Percent? Money Woes Trump Science at SfN
- René Spiegel on London: What Regulators Say About Trials in Familial AD
- David Gillam on Focus on the Locus! (Ceruleus, That Is, in Alzheimer’s Disease)
- Lary Walker on San Diego: TDP-43 Targets Loom Large—But Where’s the Bull’s Eye?
- Steven Brenner on Focus on the Locus! (Ceruleus, That Is, in Alzheimer’s Disease)
- Steven Brenner on San Diego: ALS Research Goes to the Dogs
- Robert Vassar on Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes.
- Elizabeth Heilig on Mutation analysis of the presenilin 1 N-terminal domain reveals a broad spectrum of gamma-secretase activity toward amyloid precursor protein and other substrates.
- Hans-Ulrich Demuth on Identification of low molecular weight pyroglutamate A{beta} oligomers in Alzheimer disease: a novel tool for therapy and diagnosis.
- Kiumars Lalezarzadeh on The AD8—Dementia Screen Ready for Prime Time?
- Sam Gandy on Genome-wide screen identifies rs646776 near sortilin as a regulator of progranulin levels in human plasma.
- Mikko Laakso on Indianapolis: Neuroimaging Opens Window to Disease, Better Diagnosis
- James Galvin on The AD8—Dementia Screen Ready for Prime Time?
- Gilbert J. Ho on A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain.
- Emory Hill on The AD8—Dementia Screen Ready for Prime Time?